Arkolith/Insider Trading/HALO/Form 4

Torley Helen

PRESIDENT AND CEO, DirectorHALOZYME THERAPEUTICS, INC. (HALO) · full profile →Form 4 · filed Jun 4, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$3.4M
Net Open-Market Flow
-$3.4M
Transactions
15
12 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 3, 2026Sell(S)400$66.37$27K777K
Jun 3, 2026Sell(S)2K$67.67$102K776K
Jun 3, 2026Sell(S)2K$68.74$137K774K
Jun 3, 2026Sell(S)6K$69.69$425K768K
Jun 3, 2026Option exercise(M)10K$12.07$121K778K
Jun 2, 2026Sell(S)17K$66.31$1.1M771K
Jun 2, 2026Sell(S)3K$66.75$227K768K
Jun 2, 2026Option exercise(M)20K$12.07$241K788K
Jun 1, 2026Option exercise(M)20K$12.07$241K788K
Jun 1, 2026Sell(S)2K$66.39$107K786K
Jun 1, 2026Sell(S)13K$67.41$876K773K
Jun 1, 2026Sell(S)5K$68.35$369K768K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 3, 2026Option exercise(M)10K$12.07$121K2K
Jun 2, 2026Option exercise(M)20K$12.07$241K12K
Jun 1, 2026Option exercise(M)20K$12.07$241K32K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001159036-26-000074) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML